Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

  • Technology appraisal guidance
  • TA121
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Wessex Institute for Health Research and Development, University of Southampton.

  • Garside R, Pitt M, Anderson R et al. The effectiveness and cost effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma: a systematic review and economic evaluation, September 2005.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Link Pharmaceuticals Ltd

  • Schering-Plough Ltd

II) Professional/specialist and patient/carer groups:

  • Association of British Neurologists

  • Brain and Spine Foundation

  • British Brain Tumour Association

  • British Oncological Association

  • British Oncology Pharmacy Association

  • British Psychosocial Oncology Society

  • Cancerbackup

  • Cancer Research UK

  • Cancer Voices

  • Denbighshire Local Health Board

  • Department of Health

  • Gedling PCT

  • Long-Term Medical Conditions Alliance

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • National Cancer Alliance

  • National Council for Hospice and Specialist Palliative Care Services

  • National Hospital for Neurology and Neurosurgery

  • Neurological Alliance

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Royal College of Surgeons

  • Royal Pharmaceutical Society

  • Samantha Dickson Research Trust

  • Society of British Neurological Surgeons

  • Tenovus Cancer Information Centre

  • UK Brain Tumour Society

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • Board of Community Health Councils in Wales

  • Bristol-Myers Squibb Pharmaceuticals Ltd

  • British National Formulary

  • Cambridge Laboratories

  • Clonmel Healthcare Ltd

  • Institute of Cancer Research

  • Mayne Pharma plc

  • Medac UK

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Collaborating Centre for Cancer

  • National Coordinating Centre for Health Technology Assessment

  • National Public Health Service for Wales

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group, University of Exeter

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Michael Brada, Professor of Clinical Oncology Institute of Cancer Research, nominated by the Institute of Cancer Research – clinical specialist

  • Professor Garth Cruickshank, Consultant Neurosurgeon, Society of British Neurological Surgeons, nominated by the Society of British Neurological Surgeons – clinical specialist

  • Dr Jeremy Rees, Consultant Neurologist, Institute of Neurology, nominated by the Association of British Neurologists – clinical specialist

  • Professor David Walker, Professor of Paediatric Oncology, Queen's Medical Centre, nominated by UK Brain Tumour Society – clinical specialist

  • Mr. Colin Watts, Clinical Scientist and Consultant Neurosurgeon, Cambridge University, nominated by the Society of British Neurological Surgeons – clinical specialist

  • Mrs Tina Mitchell, Chairman, Hammer Out (Brain Tumours), nominated by Brain and Spine Foundation – patient expert

  • Ms Jane Redman, nominated by the Samantha Dickson Research Trust – patient expert